Nasdaq

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings ...
Yahoo

Stool tests like Cologuard are gaining popularity over colonoscopy. Which should you get?

What if you didn't have to get a colonoscopy every decade from ages 45 to 75? No, this isn't an excuse to skip screening for colon cancer, which has been proven to save lives. But there are several ...
Nasdaq

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Hosted on MSN

Unexpected colon cancer screening test show up at your door? This may be why

(NEXSTAR) — An unexpected delivery at your door may not always be an unwelcome surprise — just ask one Kentucky boy about the thousands of dollars worth of lollipops that arrived at his home earlier ...
Seeking Alpha

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for ...

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...
The Journal Times

Exact Sciences' Cologuard cancer test debuts

JUDY NEWMAN , 608-252-6156 Aug 31, 2014 Aug 31, 2014 0 Exact Sciences’ spanking clean, new labs in the Novation Campus, off Rimrock Road, sit waiting for the rush to begin. Their mission: to examine ...
Business Wire

FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...
USA Today

Early detection matters: Screening for colon cancer at home can help

Kam knew it was important to get screened for colon cancer as soon as she was eligible. With her dad’s side of the family being affected by breast, kidney and prostate cancer, Kam wanted to “get all ...
Business Wire

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the ...
Morningstar

Exact Sciences: Encouraging Cologuard Results Make Investors Hopeful, but No Change To Fair Value

Exact Sciences EXAS released strong test results for its next-generation Cologuard test that pushed shares up 9% in after-hours trading. The strength of these results has made investors hopeful that ...

Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...